Yonhap Infomax NewsJan 26
Samsung Bioepis posts sharp 60% year-on-year drop in Q4 operating profit, signaling challenges for South Korea's biosimilar sector.
#YonhapInfomax #SamsungBioepis #OperatingProfit #Q4Earnings #Biosimilar #YearOnYearDrop #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=102024
Samsung Bioepis Q4 Operating Profit Plunges 60% to 29.2 Billion Won

Samsung Bioepis posts sharp 60% year-on-year drop in Q4 operating profit, signaling challenges for South Korea's biosimilar sector.

Yonhap Infomax
Yonhap Infomax NewsJan 15
Samsung Bioepis Holdings announced plans to expand into new drug development, leveraging its biosimilar success, with a goal of 20 products by 2030 and annual clinical-stage candidates, as outlined by CEO Kim Kyung-ah at the JP Morgan Healthcare Conference.
#YonhapInfomax #SamsungBioepisHoldings #Biosimilar #NewDrugDevelopment #JPmorganHealthcareConference #KimKyungAh #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=100079
Samsung Bioepis Holdings to Expand New Drug Development on Biosimilar Success

Samsung Bioepis Holdings announced plans to expand into new drug development, leveraging its biosimilar success, with a goal of 20 products by 2030 and annual clinical-stage candidates, as outlined by CEO Kim Kyung-ah at the JP Morgan Healthcare Conference.

Yonhap Infomax
Yonhap Infomax NewsDec 16
Celltrion has launched its biosimilar ophthalmic drug Eydenzelt in major European markets, securing NHS tenders in the UK and expanding its presence across Europe to accelerate prescriptions, targeting a share of the $9.5 billion global market for Eylea.
#YonhapInfomax #Celltrion #Eydenzelt #Biosimilar #EuropeanMarket #EyleaSales #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=95705
Tin hot mỗi ngàyNov 13

🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nh ất thế giới

🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nhất thế giới 💖👉🍀🍀🤔 #ungthu #Keytruda #miendich #Merck #biosimilar #suckhoe 1️⃣ Vị thế số một của Keytruda trên thị trường toàn cầu 

Trong vòng một thập niên, Keytruda (Pembrolizumab) của Merck đã tạo nên kỷ lục hiếm có: doanh thu vượt 146 tỷ USD, trở thành thuốc ung thư bán chạy nhất thế giới.

https://tinmoitrongngay2.wordpress.com/2025/11/13/%f0%9f%8c%bf-toan-canh-keytruda-thuoc-ung-thu-ban-chay-nh-at-the-gioi-2/

🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nh ất thế giới

🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nhất thế giới 💖👉🍀🍀🤔 #ungthu #Keytruda #miendich #Merck #biosimilar #suckhoe 1️⃣ Vị thế số một của Keytruda trên thị trường toàn cầu 

Trong vòng một th…

Tin mới trong ngày
Tin hot mỗi ngàyNov 13

🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nh ất thế giới

🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nhất thế giới 💖👉🍀🍀🤔 #ungthu #Keytruda #miendich #Merck #biosimilar #suckhoe 1️⃣ Vị thế số một của Keytruda trên thị trường toàn cầu 

Trong vòng một thập niên, Keytruda (Pembrolizumab) của Merck đã tạo nên kỷ lục hiếm có: doanh thu vượt 146 tỷ USD, trở thành thuốc ung thư bán chạy nhất thế giới.

https://tinmoitrongngay2.wordpress.com/2025/11/13/%f0%9f%8c%bf-toan-canh-keytruda-thuoc-ung-thu-ban-chay-nh-at-the-gioi/

🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nh ất thế giới

🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nhất thế giới 💖👉🍀🍀🤔 #ungthu #Keytruda #miendich #Merck #biosimilar #suckhoe 1️⃣ Vị thế số một của Keytruda trên thị trường toàn cầu 

Trong vòng một th…

Tin mới trong ngày
Jeff Levin-Scherz MDNov 6
Today in #Employer Coverage: The US lags in savings from #biosimilar medications. New regs are a step in the right direction. https://employercoverage.substack.com/p/the-us-lags-in-savings-from-biosimilar
Yonhap Infomax NewsNov 3
Celltrion has received additional FDA approval for its Yuflyma 10mg pre-filled syringe, expanding its US high-concentration biosimilar lineup for pediatric autoimmune treatment.
#YonhapInfomax #Celltrion #Yuflyma #FDAApproval #Biosimilar #JuvenileIdiopathicArthritis #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=88896
Celltrion Secures Additional FDA Approval for Yuflyma 10mg Formulation in US

Celltrion has received additional FDA approval for its Yuflyma 10mg pre-filled syringe, expanding its US high-concentration biosimilar lineup for pediatric autoimmune treatment.

Yonhap Infomax
Yonhap Infomax NewsOct 15
Celltrion has received regulatory approval in New Zealand for Stekeyma, its biosimilar to Stelara, expanding access to autoimmune disease treatments in a $21.66 billion global market.
#YonhapInfomax #Celltrion #Stekeyma #Biosimilar #Ustekinumab #NewZealandApproval #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=85542
Celltrion Secures Regulatory Approval for Autoimmune Disease Biosimilar 'Stekeyma' in New Zealand

Celltrion has received regulatory approval in New Zealand for Stekeyma, its biosimilar to Stelara, expanding access to autoimmune disease treatments in a $21.66 billion global market.

Yonhap Infomax
Yonhap Infomax NewsOct 10
Celltrion has secured US FDA approval for its Eylea biosimilar, Eydenzelt, expanding its US portfolio, though commercial launch is delayed amid ongoing patent litigation with Regeneron.
#YonhapInfomax #Celltrion #FDAApproval #Eydenzelt #Biosimilar #PatentDispute #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=84948
Celltrion Receives US FDA Approval for Ophthalmic Drug ‘Eylea’

Celltrion has secured US FDA approval for its Eylea biosimilar, Eydenzelt, expanding its US portfolio, though commercial launch is delayed amid ongoing patent litigation with Regeneron.

Yonhap Infomax
Yonhap Infomax NewsSep 22
Celltrion has obtained Japanese regulatory approval for its Actemra biosimilar Avtozma, targeting key autoimmune indications and aiming to expand its presence in Japan’s pharmaceutical market.
#YonhapInfomax #Celltrion #Avtozma #Biosimilar #JapanApproval #AutoimmuneDiseases #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=82759
Celltrion Secures Regulatory Approval for Autoimmune Disease Biosimilar 'Avtozma' in Japan

Celltrion has obtained Japanese regulatory approval for its Actemra biosimilar Avtozma, targeting key autoimmune indications and aiming to expand its presence in Japan’s pharmaceutical market.

Yonhap Infomax